## Gillian Hunt

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1884533/publications.pdf

Version: 2024-02-01

430874 794594 1,468 19 18 19 h-index citations g-index papers 19 19 19 2472 citing authors docs citations times ranked all docs

#	Article	IF	Citations
1	HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis. Lancet Infectious Diseases, The, 2018, 18, 346-355.	9.1	290
2	Global and regional molecular epidemiology of HIV-1, 1990–2015: a systematic review, global survey, and trend analysis. Lancet Infectious Diseases, The, 2019, 19, 143-155.	9.1	255
3	Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study. Lancet Infectious Diseases, The, 2016, 16, 565-575.	9.1	217
4	Reuse of Nevirapine in Exposed HIV-Infected Children After Protease Inhibitor–Based Viral Suppression. JAMA - Journal of the American Medical Association, 2010, 304, 1082.	7.4	75
5	Persistent Minority K103N Mutations among Women Exposed to Singleâ€Dose Nevirapine and Virologic Response to Nonnucleoside Reverseâ€Transcriptase Inhibitor–Based Therapy. Clinical Infectious Diseases, 2009, 48, 462-472.	5.8	74
6	Drug resistance among newly diagnosed HIV-infected children in the era of more efficacious antiretroviral prophylaxis. Aids, 2014, 28, 1673-1678.	2.2	65
7	Evaluation of sequence ambiguities of the HIV-1 pol gene as a method to identify recent HIV-1 infection in transmitted drug resistance surveys. Infection, Genetics and Evolution, 2013, 18, 125-131.	2.3	58
8	Occult HIV-1 drug resistance to thymidine analogues following failure of first-line tenofovir combined with a cytosine analogue and nevirapine or efavirenz in sub Saharan Africa: a retrospective multi-centre cohort study. Lancet Infectious Diseases, The, 2017, 17, 296-304.	9.1	58
9	Switching children previously exposed to nevirapine to nevirapine-based treatment after initial suppression with a protease-inhibitor-based regimen: long-term follow-up of a randomised, open-label trial. Lancet Infectious Diseases, The, 2012, 12, 521-530.	9.1	51
10	Trends in Pretreatment HIV-1 Drug Resistance in Antiretroviral Therapy-naive Adults in South Africa, 2000–2016: A Pooled Sequence Analysis. EClinicalMedicine, 2019, 9, 26-34.	7.1	51
11	Efavirenz-Based Antiretroviral Therapy Among Nevirapine-Exposed HIV-Infected Children in South Africa. JAMA - Journal of the American Medical Association, 2015, 314, 1808.	7.4	40
12	Low-Abundance Drug-Resistant HIV-1 Variants in Antiretroviral Drug-Naive Individuals: A Systematic Review of Detection Methods, Prevalence, and Clinical Impact. Journal of Infectious Diseases, 2020, 221, 1584-1597.	4.0	40
13	Human Immunodeficiency Virus (HIV) Drug Resistance in African Infants and Young Children Newly Diagnosed With HIV: A Multicountry Analysis. Clinical Infectious Diseases, 2017, 65, 2018-2025.	5.8	36
14	Multi-Laboratory Comparison of Next-Generation to Sanger-Based Sequencing for HIV-1 Drug Resistance Genotyping. Viruses, 2020, 12, 694.	3.3	34
15	HIV-1 Subtype A, D, G, AG and Unclassified Sequences Identified in South Africa. AIDS Research and Human Retroviruses, 2002, 18, 681-683.	1.1	30
16	Rapid Development of Antiretroviral Drug Resistance Mutations in HIV-Infected Children Less Than Two Years of Age Initiating Protease Inhibitor-Based Therapy in South Africa. AIDS Research and Human Retroviruses, 2011, 27, 945-956.	1.1	29
17	Mutational Correlates of Virological Failure in Individuals Receiving a WHO-Recommended Tenofovir-Containing First-Line Regimen: An International Collaboration. EBioMedicine, 2017, 18, 225-235.	6.1	28
18	Moderate-to-High Levels of Pretreatment HIV Drug Resistance in KwaZulu-Natal Province, South Africa. AIDS Research and Human Retroviruses, 2019, 35, 129-138.	1.1	21

#	Article	IF	CITATIONS
19	HIV drug resistance profile in South Africa: Findings and implications from the 2017 national HIV household survey. PLoS ONE, 2020, 15, e0241071.	2.5	16